Form 4: Hims & Hers CEO Sells $11M in Stock via 10b5-1 Plan

Hims & Hers Health, Inc. CEO Andrew Dudum executed planned sales of over 175,000 Class A Common Stock shares totaling approximately $11 million.

Summary

• Andrew Dudum, Chief Executive Officer, Director, and 10% Owner of Hims & Hers Health, Inc., executed multiple transactions on October 16, 2025.
• Transactions included the exercise of stock options to acquire a total of 125,335 shares of Class A Common Stock at an exercise price of $2.43 per share.
• Simultaneously, Dudum sold a total of 175,661 shares of Class A Common Stock at weighted average prices ranging from $62.6518 to $63.4852.
• The estimated total value of shares sold is approximately $11 million.
• All reported stock option exercises and sales were conducted under a Rule 10b5-1 trading plan adopted on August 28, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, which mitigates concerns about reactive selling based on new information. The high sale price relative to the exercise price indicates a positive outcome for the insider's personal financial planning.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale based on new information.
• The sale prices for Class A Common Stock were significantly higher than the option exercise price of $2.43, indicating substantial gains for the reporting person.

Negatives

• A significant volume of insider selling (175,661 shares) by the CEO, Director, and 10% owner could be perceived negatively by some investors, despite being pre-planned.

Future Outlook

This filing, a Form 4, primarily reports insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The stock option exercises and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
• The Reporting Person undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Industry Context

This Form 4 filing details insider trading activity and does not provide information related to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by a key executive, even if pre-planned, could lead to short-term market speculation or a slight downward pressure on the stock price due to increased supply.
• Shareholders: The execution of transactions under a Rule 10b5-1 plan provides transparency and indicates a structured approach to insider stock sales, which can be viewed positively for corporate governance.

Key Dates

Recommendation

The filing reports routine insider transactions executed under a pre-arranged Rule 10b5-1 plan. While the sale of a significant number of shares by the CEO might typically raise concerns, the pre-planned nature mitigates the signal of negative insider sentiment. The transactions reflect the exercise of options and subsequent sale for personal financial planning, rather than a reaction to new company-specific information. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, CEO, Director, 10% Owner